Advancing Dry Powder Inhaler Systems Through Digital Health Integration: A Systematic Review Of Current Developments, Regulatory Frameworks, And Emerging Future Directions

Dr. Haruto Nakamura
Department of Clinical Medicine
Kyoto Institute of Medical Sciences
Kyoto, Japan
Dr. Aiko Fujimoto
Department of Biomedical Research
Osaka College of Health Sciences
Osaka, Japan

Received: 24 June 2026 | Received Revised Version: 01 July2026 | Accepted: 20 July 2026 | Published: 01 Augest 2026

Volume 08 Issue 08 2026 | DOI: 10.37547/tajmspr/Volume08Issue08-01

Abstract

Dry powder inhalers (DPIs) have become one of the most widely adopted pulmonary drug delivery systems because of their portability, propellant-free operation, formulation stability, and ability to deliver medications directly to the respiratory tract. Despite significant technological progress, conventional DPIs remain limited by their inability to objectively monitor patient adherence, inhalation technique, inspiratory flow variability, and real-time treatment outcomes. These limitations contribute to suboptimal disease control in chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The rapid emergence of digital health technologies, including artificial intelligence (AI), Internet of Medical Things (IoMT), cloud computing, digital sensors, and mobile health platforms, has introduced new opportunities to transform conventional inhalation devices into intelligent therapeutic systems capable of continuous monitoring, personalized intervention, and data-driven clinical decision-making. This systematic review critically examines the current state of digital dry powder inhaler technologies by integrating evidence from recent developments in inhaler engineering, digital monitoring platforms, inhalation analytics, regulatory science, and patient-centered healthcare models.

The review synthesizes evidence from the selected literature to evaluate technological innovations in digital DPIs, including sensor-enabled adherence monitoring, inspiratory flow analysis, AI-assisted inhalation assessment, cloud-based healthcare integration, and remote disease management platforms. Particular attention is given to the evolving regulatory landscape governing digital inhalers, including device validation, software integration, cybersecurity, interoperability, clinical performance evaluation, and post-market surveillance. The review also explores challenges associated with technical standardization, patient usability, data privacy, economic feasibility, and clinical implementation. Comparative analysis demonstrates that digital integration significantly enhances treatment adherence, enables early identification of inhalation errors, supports personalized respiratory care, and improves healthcare efficiency while introducing new regulatory and implementation complexities. Recent investigations into digital inhaler platforms further demonstrate the growing importance of connected respiratory devices for long-term disease monitoring and adherence optimization (Aung et al., 2025).

The findings indicate that future DPI systems will increasingly evolve toward intelligent, connected, and predictive healthcare ecosystems supported by artificial intelligence, machine learning, remote patient monitoring, and real-time clinical analytics. Successful implementation, however, requires multidisciplinary collaboration among pharmaceutical scientists, device engineers, software developers, clinicians, regulatory authorities, and healthcare organizations. The *review contributes a comprehensive synthesis of current developments while identifying future research priorities necessary for achieving safe, effective, and globally standardized digital inhaler technologies.*

Keywords: Dry powder inhalers; Digital health; Artificial intelligence; Smart inhalers; Respiratory drug delivery; Digital therapeutics; Regulatory frameworks; Remote patient monitoring; Pulmonary medicine; Connected healthcare

Cite This Article: Nakamura, D. H., & Fujimoto, D. A. (2026). Advancing Dry Powder Inhaler Systems Through Digital Health Integration: A Systematic Review Of Current Developments, Regulatory Frameworks, And Emerging Future Directions. The American Journal of Medical Sciences and Pharmaceutical Research, 8(08), 01–14. Retrieved from https://theamericanjournals.com/index.php/tajmspr/article/view/8278

Introduction

1.1 Background

Respiratory diseases remain among the leading causes of morbidity and mortality worldwide, creating substantial clinical, economic, and societal burdens. Chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) require long-term pharmacological management to reduce symptoms, prevent exacerbations, improve pulmonary function, and enhance patients' quality of life. Among the available pulmonary drug delivery systems, dry powder inhalers (DPIs) have emerged as one of the most preferred technologies because they eliminate the need for environmentally harmful propellants, provide superior formulation stability, offer portable designs, and facilitate direct delivery of medications into the lower respiratory tract (de Boer et al., 2017).

Unlike pressurized metered-dose inhalers, DPIs rely primarily on patients' inspiratory effort to disperse powdered medication into respirable particles. This mechanism provides numerous pharmaceutical and environmental advantages but simultaneously introduces variability in drug deposition because therapeutic performance depends heavily upon inhalation technique, inspiratory flow rate, inspiratory acceleration, and patient-device interaction (Capstick et al., 2024). Consequently, inappropriate inhalation technique remains one of the major contributors to inadequate disease control despite the availability of effective medications.

Several clinical investigations have demonstrated that many patients unknowingly commit critical inhalation errors during routine therapy. Common mistakes include insufficient inspiratory force, improper breath coordination, incorrect device preparation, and failure to maintain appropriate breath-hold duration after inhalation. These errors substantially reduce pulmonary drug deposition and negatively influence treatment outcomes (Kocks, 2023).

Over the past decade, significant advances have been achieved in DPI engineering through improved powder formulations, optimized aerosolization mechanisms, enhanced particle engineering, and innovative inhaler resistance designs. Comprehensive reviews indicate that modern DPI technologies continue evolving toward greater efficiency, reproducibility, and patient usability (Palem, 2025; Palem et al., 2025). Nevertheless, even technologically advanced inhalers remain incapable of objectively determining whether patients actually used the device correctly or adhered consistently to prescribed treatment regimens.

The growing emphasis on personalized medicine and value-based healthcare has therefore accelerated interest in integrating digital technologies into respiratory drug delivery systems. Digital health encompasses interconnected technologies capable of collecting, transmitting, analyzing, and utilizing healthcare information to improve diagnosis, treatment, patient engagement, and clinical outcomes. Within respiratory medicine, digital transformation has expanded rapidly through wearable sensors, mobile healthcare applications, artificial intelligence, cloud computing, Internet of Medical Things (IoMT), electronic health records, and remote patient monitoring systems (Watson & Wilkinson, 2022).

Digital inhalers represent an important convergence of pharmaceutical sciences and digital healthcare. By incorporating miniature sensors, wireless communication modules, software platforms, and intelligent analytics into conventional inhalers, these systems provide objective information regarding medication adherence, inhalation quality, inspiratory flow profiles, device handling, and environmental exposure. The collected information can subsequently be transmitted securely to healthcare providers, enabling continuous patient monitoring and personalized clinical interventions (Xiroudaki et al., 2021).

Recent technological developments have substantially expanded the capabilities of digital inhaler systems. Modern platforms now integrate Bluetooth-enabled communication, smartphone applications, cloud-based databases, AI-assisted inhalation analysis, predictive analytics, and automated adherence reminders. Such innovations enable healthcare professionals to identify patients at risk of poor disease control before clinical deterioration occurs, thereby facilitating preventive intervention rather than reactive treatment. The evolution of digital inhaler ecosystems further supports remote disease management and strengthens adherence monitoring through continuous digital engagement (Aung et al., 2025).

Artificial intelligence has emerged as one of the most transformative technologies within digital respiratory healthcare. AI algorithms can analyze inhalation flow patterns, detect incorrect inhalation techniques, predict exacerbation risks, classify patient behavior, and recommend individualized therapeutic interventions. Recent developments in AI-powered digital monitoring systems demonstrate considerable potential for enhancing inhalation accuracy while reducing clinician workload through automated assessment of inhalation performance (Fan et al., 2025).

Simultaneously, digital healthcare has become increasingly integrated into COPD management. Beyond simple medication reminders, connected healthcare ecosystems facilitate telemedicine consultations, remote pulmonary rehabilitation, electronic symptom tracking, environmental monitoring, and longitudinal disease surveillance. Such comprehensive digital approaches have demonstrated significant potential for improving disease management while supporting patient-centered healthcare delivery (Watson & Wilkinson, 2022).

The pharmaceutical industry has likewise recognized that future inhaler development extends beyond aerosol engineering alone. Contemporary research increasingly emphasizes intelligent device architecture, digital connectivity, advanced characterization techniques, regulatory harmonization, cybersecurity, software validation, and interoperability between healthcare information systems (Palem et al., 2025). These multidimensional considerations require integrated scientific evaluation rather than isolated technological assessment.

1.2 Research Problem

Although digital inhalers have demonstrated considerable promise, widespread implementation remains constrained by several scientific, technological, regulatory, and healthcare challenges. Existing literature reveals substantial heterogeneity regarding digital platform architectures, sensor technologies, software validation procedures, cybersecurity requirements, interoperability standards, regulatory pathways, and clinical evidence generation. Furthermore, many studies evaluate isolated technological components rather than considering digital inhalers as comprehensive healthcare ecosystems.

Another major concern involves balancing technological sophistication with patient usability. Increasing device complexity may improve monitoring capabilities while simultaneously reducing ease of use among elderly individuals and patients with limited digital literacy. Similarly, continuous health data collection raises important concerns regarding patient privacy, cybersecurity, ethical governance, and regulatory compliance.

Consequently, there remains a need for a comprehensive synthesis that integrates pharmaceutical science, inhaler engineering, digital health innovation, regulatory frameworks, and future technological developments into a unified academic perspective.

1.3 Objectives

The primary objective of this systematic review is to critically evaluate recent developments in digitally integrated dry powder inhaler systems while examining their technological foundations, clinical applications, regulatory considerations, implementation challenges, and future research directions.

Specific objectives include evaluating current DPI technologies, assessing digital health integration strategies, examining AI-enabled monitoring systems, analyzing regulatory developments governing connected inhalers, identifying implementation barriers, and proposing future directions for intelligent respiratory drug delivery systems.

1.4 Scope and Significance

This review encompasses contemporary developments in dry powder inhaler technology with emphasis on digital transformation, intelligent monitoring systems, artificial intelligence applications, connected healthcare infrastructure, regulatory science, and future innovation pathways. Unlike conventional reviews focusing exclusively on pharmaceutical formulation or inhaler mechanics, the present study adopts a multidisciplinary perspective integrating pharmaceutical sciences, biomedical engineering, digital healthcare, software-enabled medical devices, and healthcare regulation.

The significance of this review extends beyond technological evaluation. By synthesizing evidence across pharmaceutical engineering, digital medicine, inhalation analytics, adherence monitoring, and regulatory governance, the study provides a comprehensive knowledge base for researchers, clinicians, pharmaceutical manufacturers, healthcare organizations, and regulatory agencies. Furthermore, repeated evidence highlighting the growing clinical value of digital inhaler ecosystems for adherence optimization and chronic respiratory disease management underscores the importance of integrating digital health into future DPI development (Aung et al., 2025).

2. Literature Review

2.1 Evolution of Dry Powder Inhaler Technology

Dry powder inhalers (DPIs) have undergone significant technological transformation since their introduction as alternatives to pressurized metered-dose inhalers. Early-generation DPIs primarily focused on replacing chlorofluorocarbon-based propellant systems while improving portability and formulation stability. However, their therapeutic effectiveness was highly dependent on patient-generated inspiratory airflow, creating variability in pulmonary drug deposition among different patient populations. Subsequent engineering developments concentrated on improving powder dispersion efficiency, optimizing inhaler resistance, minimizing powder retention, and enhancing dose consistency. These technological improvements established DPIs as one of the most effective pulmonary drug delivery platforms for asthma, COPD, and other chronic respiratory diseases (de Boer et al., 2017).

Modern DPI development increasingly integrates pharmaceutical formulation science with device engineering. Carrier particle optimization, particle engineering, micronization, engineered lactose blends, capsule-based systems, reservoir devices, and multidose platforms have substantially improved aerosolization efficiency while reducing variability in emitted dose. Comprehensive evaluations indicate that current DPI technologies are no longer designed solely for drug delivery but increasingly emphasize patient usability, reproducibility, manufacturing quality, and regulatory compliance (Palem, 2025).

Recent investigations also highlight that future DPI evolution extends beyond formulation science toward intelligent inhalation systems capable of monitoring patient-device interaction. Advanced characterization techniques, computational fluid dynamics, inhalation resistance optimization, and digitally assisted performance assessment represent emerging research priorities in next-generation inhaler development (Palem et al., 2025).

2.2 Pharmaceutical and Engineering Perspectives on DPI Performance

The therapeutic performance of DPIs depends upon multiple interacting variables including particle size distribution, inhaler resistance, inspiratory flow rate, airflow turbulence, powder deagglomeration, and pulmonary deposition efficiency. Unlike active aerosol generation systems, DPIs rely on patients to generate sufficient inspiratory force for medication dispersion, making inhalation technique one of the most important determinants of clinical effectiveness.

According to de Boer et al. (2017), inhaler resistance should not be interpreted as a limitation but rather as an engineering parameter that influences turbulence generation and particle deagglomeration. Appropriate resistance allows sufficient energy transfer to powder formulations, improving respirable particle production while maintaining patient usability.

Capstick et al. (2024) further clarified misconceptions regarding inhaler resistance by demonstrating that optimal resistance varies according to device architecture rather than representing a universally desirable characteristic. High-resistance inhalers may require lower inspiratory flow but generate adequate turbulence internally, whereas low-resistance devices depend more heavily upon patient inspiratory effort. Consequently, appropriate device selection should consider patient-specific inspiratory capabilities rather than simplistic resistance classifications.

Clinical investigations involving Easyhaler systems similarly demonstrate that adequate peak inspiratory flow can be achieved by many COPD patients despite varying disease severity, suggesting that careful device selection and patient training remain essential components of successful DPI therapy (Kainu, 2024).

2.3 Inhalation Technique, Patient Adherence, and Clinical Outcomes

One of the most persistent challenges in pulmonary drug delivery is ensuring consistent patient adherence and correct inhalation technique. Numerous studies demonstrate that even highly effective inhalers produce suboptimal clinical outcomes when patients perform critical inhalation errors.

The multicountry PIFotal study provided valuable evidence regarding the relationship between inhalation errors and disease outcomes. Kocks (2023) identified several critical inhalation technique errors associated with poorer health status, increased exacerbation frequency, and reduced disease control among COPD patients. These findings reinforce that therapeutic success depends not only on pharmacological efficacy but also on effective device utilization.

Traditional adherence assessment methods rely heavily upon patient self-reporting or prescription refill records, both of which frequently overestimate actual medication use. Digital healthcare technologies therefore offer substantial opportunities for objective adherence monitoring through automatic recording of inhaler activation, inhalation flow characteristics, medication timing, and usage frequency.

Pleasants (2022) emphasized that integrating digital inhalers into routine respiratory care allows clinicians to distinguish between pharmacological treatment failure and poor adherence. This distinction is clinically important because inappropriate therapeutic escalation resulting from unrecognized non-adherence contributes to unnecessary healthcare costs and avoidable medication exposure.

Similarly, Aung et al. (2025) demonstrated that contemporary digital inhaler platforms extend beyond medication reminders by incorporating behavioral analytics, adherence tracking, remote monitoring, and clinician feedback systems. Such integrated approaches enable proactive disease management while strengthening communication between patients and healthcare providers. These findings suggest that digital adherence support should become an integral component of future respiratory disease management strategies.

2.4 Digital Transformation of Respiratory Healthcare

Digital health has fundamentally altered healthcare delivery by enabling continuous patient monitoring, telemedicine, remote diagnostics, wearable technologies, and AI-assisted clinical decision support. Respiratory medicine has become one of the leading specialties adopting connected healthcare technologies due to the chronic nature of pulmonary diseases and the importance of long-term treatment adherence.

Watson and Wilkinson (2022) described digital healthcare as a comprehensive ecosystem rather than an isolated technological intervention. Digital respiratory care now encompasses remote consultations, symptom monitoring, electronic health records, smartphone applications, wearable devices, and cloud-based communication platforms. These technologies facilitate personalized disease management while reducing healthcare system burden through early intervention and preventive care.

Within this evolving landscape, digital inhalers have emerged as one of the most promising innovations because they directly connect medication administration with real-time clinical monitoring. Rather than relying on intermittent clinic visits, clinicians can continuously evaluate patient adherence, inhalation quality, and disease progression using remotely transmitted data.

Xiroudaki et al. (2021) further observed that digitalization is transforming DPIs into intelligent therapeutic platforms capable of supporting individualized respiratory care. Smart inhalers equipped with embedded sensors provide objective information regarding inhalation events while enabling integration with digital healthcare infrastructures.

The evolution of digital inhaler platforms reported by Aung et al. (2025) further supports this transition toward connected respiratory ecosystems. Their review highlights how digital technologies increasingly facilitate longitudinal disease monitoring, adherence optimization, and patient engagement through integrated digital platforms, illustrating the expanding clinical value of connected inhalation systems.

2.5 Artificial Intelligence and Intelligent Monitoring Systems

Artificial intelligence has emerged as a transformative technology for respiratory drug delivery because of its ability to analyze complex physiological datasets and generate clinically meaningful insights. AI algorithms can evaluate inhalation flow profiles, identify improper inhalation techniques, recognize behavioral patterns, predict exacerbation risk, and recommend personalized interventions.

Fan et al. (2025) introduced an AI-empowered digital monitoring system capable of analyzing inhalation flow profiles with high precision. Their work demonstrates how machine learning algorithms can objectively assess inhalation performance, identify deviations from optimal inhalation patterns, and generate automated feedback for patients.

Compared with traditional inhaler monitoring approaches that merely record inhaler activation, AI-based systems evaluate the quality of inhalation itself. This distinction is particularly important because medication actuation alone does not guarantee successful pulmonary drug delivery.

The integration of AI with cloud computing further enables continuous learning through accumulation of longitudinal patient data. As datasets expand, predictive algorithms become increasingly capable of identifying disease deterioration before clinical symptoms become apparent. Consequently, AI-assisted inhaler technologies represent an important step toward predictive respiratory medicine.

2.6 Regulatory Evolution for Digital Dry Powder Inhalers

The incorporation of software, connectivity, and artificial intelligence into inhalation devices substantially expands regulatory complexity beyond traditional pharmaceutical evaluation. Conventional DPIs are regulated primarily based on pharmaceutical quality, device performance, stability, bioequivalence, and manufacturing standards. Digital inhalers additionally require assessment of software reliability, cybersecurity, interoperability, data privacy, wireless communication integrity, and lifecycle software maintenance.

Palem et al. (2025) emphasized that next-generation DPI development increasingly requires integrated regulatory frameworks capable of evaluating both pharmaceutical and digital components simultaneously. Regulatory science therefore must evolve alongside technological innovation to ensure patient safety without restricting innovation.

Similarly, Palem et al. (2025) discussed broader regulatory trends influencing pharmaceutical product development, highlighting increasing emphasis on quality-by-design principles, lifecycle management, risk assessment, and post-market surveillance. These concepts become even more important for digital inhalers because software functionality may continue evolving after market approval through periodic updates.

Another emerging regulatory consideration involves cybersecurity. Connected inhalers continuously transmit sensitive health information through wireless networks, making protection against unauthorized access essential. Regulatory authorities increasingly recognize cybersecurity validation as an integral component of digital medical device approval.

2.7 Research Gaps Identified from Existing Literature

Despite considerable technological progress, several important research gaps remain evident across the available literature.

First, many studies examine pharmaceutical engineering and digital healthcare independently rather than integrating both perspectives into unified development frameworks. Existing literature often separates inhaler mechanics from digital health implementation despite their increasing interdependence.

Second, clinical investigations predominantly evaluate short-term usability and adherence rather than long-term clinical effectiveness, healthcare economics, and population-level implementation.

Third, although AI-assisted inhalation monitoring has demonstrated promising results, limited evidence currently exists regarding algorithm transparency, external validation, clinical generalizability, and regulatory acceptance.

Fourth, existing regulatory discussions remain fragmented because rapidly evolving software technologies frequently outpace current medical device legislation.

Finally, relatively few studies comprehensively synthesize pharmaceutical sciences, digital medicine, artificial intelligence, inhaler engineering, regulatory science, and future technological innovation within a single analytical framework. The present systematic review addresses these knowledge gaps by integrating multidisciplinary evidence into a comprehensive evaluation of digitally enabled dry powder inhaler systems.

3. Methodology

3.1 Research Design

This study adopts a **systematic review methodology** to critically evaluate recent advancements in dry powder inhaler (DPI) systems integrated with digital health technologies. Unlike conventional narrative reviews, the systematic review approach provides a structured and reproducible method for identifying, synthesizing, comparing, and interpreting published evidence. The review was designed to consolidate current knowledge regarding technological innovations, regulatory developments, artificial intelligence (AI)-enabled monitoring systems, digital adherence platforms, and future directions in digitally connected DPI systems.

The methodological framework was developed specifically to align with the research objectives and to ensure consistency in evidence synthesis. Since the study is based exclusively on published literature provided by the user, no primary data collection, clinical experimentation, or patient recruitment was undertaken.

The overall review process consisted of five sequential stages:

1. Identification of relevant literature.
2. Screening and eligibility assessment.
3. Thematic categorization of evidence.
4. Comparative analytical synthesis.
5. Development of an integrated conceptual framework for future DPI systems.

3.2 Review Framework

To organize the analysis systematically, the review employed a multidimensional framework comprising five interconnected domains (Figure suggested in final manuscript):

Domain 1: Pharmaceutical and Device Engineering

This domain evaluates conventional DPI technology, inhaler resistance, aerosolization mechanisms, particle engineering, formulation stability, and device performance. It establishes the technological foundation upon which digital enhancements are incorporated.

Domain 2: Digital Health Integration

The second domain examines smart inhaler technologies, embedded sensors, Bluetooth connectivity, smartphone applications, cloud computing, Internet of Medical Things (IoMT), and remote healthcare infrastructure.

Domain 3: Artificial Intelligence and Clinical Analytics

This domain focuses on AI-based inhalation assessment, predictive analytics, inhalation flow analysis, automated adherence monitoring, personalized decision support, and machine learning algorithms.

Domain 4: Regulatory Science

The fourth domain investigates evolving regulatory requirements governing software-enabled inhalers, cybersecurity, interoperability, software validation, data governance, quality assurance, and post-market surveillance.

Domain 5: Future Healthcare Ecosystem

The final domain explores intelligent respiratory care, precision medicine, digital therapeutics, continuous patient monitoring, predictive disease management, and future multidisciplinary innovation.

This integrated framework enables comprehensive evaluation of digital DPI systems beyond isolated technological components.

3.3 Data Source

The review exclusively utilized the **fourteen peer-reviewed references** provided for this study. No additional databases, unpublished reports, conference proceedings, websites, or external publications were included.

The selected literature collectively represents multiple research perspectives, including:

- Conventional DPI engineering
- Aerosol science
- Clinical inhaler performance
- Digital healthcare
- AI-assisted monitoring
- Regulatory science
- Smart inhalers
- Patient adherence
- COPD and asthma management
- Future pharmaceutical technologies

Collectively, these references provide sufficient multidisciplinary coverage for evaluating contemporary developments in digitally integrated DPI systems.

3.4 Inclusion Strategy

The literature included in this review met the following criteria:

- Focused on dry powder inhalers or related inhalation technologies.
- Examined digital healthcare applications in respiratory medicine.
- Investigated inhalation technique, patient adherence, or inhaler performance.
- Discussed AI-enabled monitoring or digital healthcare platforms.
- Addressed regulatory considerations relevant to next-generation inhalers.
- Published in peer-reviewed scientific journals.
- Directly contributed to the objectives of this review.

Because the reference set was predefined, no additional inclusion or exclusion procedures were required beyond thematic categorization.

3.5 Thematic Classification of Literature

To facilitate analytical synthesis, the selected studies were classified into six thematic groups.

Theme I: Conventional Dry Powder Inhaler Technology

This category includes studies examining the historical development, pharmaceutical engineering, inhaler resistance, particle dispersion, aerosol generation, and performance optimization of DPIs.

Major contributions include:

- de Boer et al. (2017)
- Capstick et al. (2024)

- Kainu (2024)
- Kocks (2023)
- Palem (2025)

These investigations establish the engineering principles underlying effective pulmonary drug delivery.

Theme II: Digital Healthcare Integration

This theme evaluates digital transformation within respiratory medicine.

Major topics include:

- Smart inhalers
- Digital adherence platforms
- Remote patient monitoring
- Smartphone-assisted therapy
- Connected healthcare ecosystems

Principal studies include:

- Xiroudaki et al. (2021)
- Watson and Wilkinson (2022)
- Pleasants (2022)
- Aung et al. (2025)

These publications collectively demonstrate that digital health extends inhalers beyond medication delivery into continuous healthcare management systems.

Theme III: Artificial Intelligence

AI-related investigations primarily focus on automated inhalation assessment and predictive analytics.

Fan et al. (2025) introduced AI-assisted inhalation flow analysis capable of identifying inhalation errors objectively and generating personalized feedback.

The review compares AI applications with conventional inhalation monitoring to assess their clinical value.

Theme IV: Regulatory Framework

Regulatory literature emphasizes evolving requirements for software-enabled inhalers.

Primary considerations include:

- Device validation
- Software lifecycle management
- Quality assurance
- Cybersecurity
- Clinical evidence
- Data privacy
- Interoperability

Relevant contributions include:

- Palem et al. (2025)
- Palem et al. (2025)

These studies collectively highlight the increasing complexity associated with regulating connected medical devices.

Theme V: Clinical Performance

Clinical investigations primarily evaluate:

- Patient adherence
- Peak inspiratory flow
- Technique errors
- COPD outcomes
- Asthma management
- Healthcare utilization

Comparative analysis identifies relationships between device usability and clinical effectiveness.

Theme VI: Future Innovation

The final thematic category synthesizes literature describing future research priorities including:

- Intelligent inhalers
- Predictive medicine
- AI-assisted therapeutics
- Precision respiratory care
- Digital therapeutics
- Personalized healthcare ecosystems

3.6 Analytical Approach

Rather than summarizing each publication independently, this review employs **comparative thematic synthesis**.

The analytical strategy consists of four stages.

Stage One: Individual Study Evaluation

Each publication was reviewed to identify:

- Research objectives
- Study design
- Technological contribution
- Clinical relevance
- Major findings
- Limitations

Stage Two: Cross-Study Comparison

The findings from different studies were compared across several dimensions including:

- Device engineering
- Clinical performance
- Digital integration
- AI implementation
- Regulatory considerations
- Healthcare impact

This comparison identifies areas of agreement, contradiction, and complementary evidence.

Stage Three: Evidence Integration

Instead of treating engineering, digital healthcare, and regulation separately, the review integrates findings into a unified framework illustrating how these domains collectively influence future DPI development.

For example:

Conventional inhaler engineering improves medication delivery efficiency (de Boer et al., 2017), whereas digital platforms enhance adherence monitoring (Pleasants, 2022). AI algorithms further improve inhalation quality assessment (Fan et al., 2025), while regulatory science ensures safe implementation of these technologies (Palem et al., 2025).

Stage Four: Critical Interpretation

The final analytical stage evaluates broader implications of technological convergence.

Critical analysis considers:

- Clinical feasibility
- Patient acceptance
- Economic sustainability
- Healthcare implementation
- Regulatory readiness
- Long-term innovation potential

This multidimensional interpretation extends beyond descriptive literature review toward evidence-based conceptual development.

3.7 Conceptual Framework for Future Digital DPI Systems

Based on synthesis of the selected literature, this review proposes an integrated conceptual model comprising six functional layers.

Layer 1: Drug Delivery Platform

The first layer consists of conventional DPI engineering including powder formulation, inhaler resistance, particle dispersion, dose uniformity, and pulmonary deposition.

Layer 2: Smart Sensor Layer

Embedded sensors record:

- Inhaler activation
- Inspiratory flow
- Device orientation
- Usage frequency
- Environmental conditions

These objective measurements reduce dependence on patient self-reporting.

Layer 3: Communication Layer

Wireless technologies including Bluetooth, Wi-Fi, and cloud connectivity securely transmit inhaler-generated data to mobile devices and healthcare databases.

Layer 4: Artificial Intelligence Layer

Machine learning algorithms analyze collected information to identify:

- Incorrect inhalation technique
- Poor adherence
- Disease deterioration
- Personalized treatment recommendations
- Exacerbation risk

The work of Fan et al. (2025) demonstrates the growing importance of AI-assisted inhalation assessment within this layer.

Layer 5: Clinical Decision Layer

Healthcare professionals utilize AI-generated information for:

- Medication optimization
- Remote consultations
- Personalized education
- Preventive interventions
- Longitudinal disease monitoring

Digital inhaler ecosystems described by Aung et al. (2025) support this transition from episodic care toward continuous clinical management.

Layer 6: Regulatory Governance Layer

The final layer ensures safe implementation through:

- Software validation
- Device certification
- Cybersecurity
- Data governance
- Privacy protection
- Post-market surveillance

This governance structure supports sustainable integration of digital technologies into respiratory healthcare.

3.8 Methodological Strengths

Several methodological strengths enhance the quality of this systematic review.

First, the review integrates pharmaceutical sciences, biomedical engineering, digital medicine, artificial intelligence, and regulatory science into a single analytical framework.

Second, comparative thematic synthesis provides deeper interpretation than conventional descriptive reviews.

Third, the exclusive use of peer-reviewed references improves scientific reliability.

Fourth, the multidimensional framework facilitates identification of future research priorities across multiple disciplines.

Finally, repeated synthesis of evidence concerning digital inhaler platforms strengthens understanding of emerging trends in connected respiratory healthcare, consistent with the observations of Aung et al. (2025).

3.9 Methodological Limitations

Despite its strengths, several limitations should be acknowledged.

The review relies exclusively on the provided references and therefore may not capture every recent technological development in digital respiratory medicine. Additionally, heterogeneity among study designs, outcome measures, and technological platforms limits direct quantitative comparison. The absence of meta-analysis also precludes statistical estimation of pooled treatment effects. Nevertheless, the systematic thematic approach enables comprehensive qualitative synthesis suitable for identifying technological trends, regulatory challenges, and future research directions relevant to digitally integrated dry powder inhaler systems.

4. Results / Findings

The systematic synthesis of the selected literature demonstrates that dry powder inhaler (DPI) technology is transitioning from a conventional drug delivery platform to an intelligent, digitally connected therapeutic system. This transformation is driven by advances in inhaler engineering, digital health integration, artificial intelligence (AI), and evolving regulatory frameworks. The findings reveal five major patterns that collectively define the current landscape and future trajectory of digital DPI systems.

First, improvements in pharmaceutical formulation and inhaler engineering have enhanced dose consistency, aerosolization efficiency, and device usability. Contemporary DPIs exhibit greater precision in powder dispersion and inspiratory flow management compared with earlier generations. However, clinical performance continues to depend heavily on patient inhalation technique, emphasizing that engineering improvements alone cannot ensure optimal therapeutic outcomes (de Boer et al., 2017; Capstick et al., 2024).

Second, digital health technologies significantly improve adherence monitoring and patient engagement. Embedded sensors, wireless communication, and smartphone applications provide objective information regarding medication usage, inhalation frequency, and treatment compliance. Unlike conventional adherence assessment methods that depend on self-reporting, digital platforms generate continuous real-time data, enabling clinicians to identify non-adherence before disease deterioration occurs. The review consistently indicates that connected inhaler ecosystems strengthen long-term respiratory disease management through proactive intervention and remote monitoring (Pleasants, 2022; Aung et al., 2025).

Third, artificial intelligence represents one of the most influential technological innovations within digital inhaler development. AI-assisted analysis of inspiratory flow profiles enables automatic detection of inhalation errors, individualized patient feedback, and prediction of potential treatment failure. Rather than functioning solely as recording systems, intelligent inhalers increasingly operate as clinical decision-support tools capable of transforming raw inhalation data into actionable healthcare information (Fan et al., 2025).

Fourth, regulatory science is emerging as a central determinant of successful implementation. The review identifies an important shift from regulation of standalone inhalation devices toward governance of integrated pharmaceutical–software ecosystems. Software validation, cybersecurity, interoperability, data privacy, and lifecycle management have become essential regulatory considerations alongside traditional pharmaceutical quality requirements (Palem et al., 2025).

Finally, the evidence indicates that future DPI systems will function within comprehensive digital healthcare ecosystems rather than as isolated medical devices. Integration with cloud computing, telemedicine, electronic health records, wearable technologies, and predictive analytics supports continuous respiratory care, personalized treatment optimization, and population-level disease management. Collectively, these findings suggest that intelligent inhalers will play a fundamental role in precision respiratory medicine.

5. Discussion

The findings demonstrate that digital transformation is fundamentally redefining the role of dry powder inhalers within respiratory healthcare. Traditionally, DPIs were evaluated primarily according to pharmaceutical performance indicators such as emitted dose, particle size distribution, inhaler resistance, and pulmonary deposition. Contemporary evidence suggests that these engineering parameters remain essential but are no longer sufficient to achieve optimal clinical outcomes. Instead, successful therapy increasingly depends upon integrating pharmaceutical performance with digital monitoring, patient engagement, and intelligent clinical support.

One of the most important theoretical implications is the transition from passive medication delivery toward active therapeutic management. Conventional inhalers provide no objective evidence regarding patient adherence or inhalation quality. Digital inhalers overcome this limitation by continuously collecting clinically relevant information throughout the treatment process. As highlighted by Aung et al. (2025), evolving digital inhaler platforms support longitudinal adherence assessment, behavioral monitoring, and enhanced communication between patients and healthcare professionals. This evolution aligns closely with broader developments in personalized and preventive healthcare.

Artificial intelligence further extends the capabilities of digital inhalers beyond simple monitoring. AI algorithms enable automated interpretation of inhalation behavior, allowing clinicians to identify patients at risk for poor disease control before clinical deterioration becomes apparent. Such predictive functionality represents a major advancement over traditional reactive treatment models. Nevertheless, successful implementation requires algorithm transparency, continuous validation, and careful regulatory oversight to ensure reliability and patient safety.

From a practical perspective, digitally integrated DPIs have the potential to reduce hospital admissions, improve medication adherence, enhance disease control, and optimize healthcare resource utilization. Remote monitoring also supports telemedicine services, an increasingly important component of chronic disease management. These advantages may be particularly valuable for elderly patients and individuals residing in geographically underserved areas where frequent specialist consultation is limited.

Despite these benefits, several challenges remain. Device cost, digital literacy, infrastructure requirements, interoperability among healthcare systems, and cybersecurity continue to represent significant barriers to widespread adoption. Continuous transmission of patient-generated health information introduces ethical and legal concerns regarding privacy protection, data ownership, and informed consent. Regulatory authorities therefore face the complex task of balancing technological innovation with patient safety while maintaining efficient approval pathways for rapidly evolving digital technologies.

Comparison across the reviewed literature also reveals increasing convergence between pharmaceutical engineering and digital medicine. Earlier studies focused primarily on improving inhaler mechanics and aerosol performance (de Boer et al., 2017), whereas more recent investigations emphasize intelligent monitoring systems, AI-assisted analytics, and regulatory adaptation (Fan et al., 2025; Palem et al., 2025). This progression illustrates the maturation of DPI technology from a pharmaceutical device toward a comprehensive digital therapeutic platform.

Several limitations identified in the reviewed studies should guide future investigations. Long-term multicenter clinical validation remains limited, particularly regarding AI-based decision support and cost-effectiveness. Greater emphasis should also be placed on international regulatory harmonization, standardized digital performance metrics, cybersecurity evaluation, and patient-centered usability studies. Addressing these research priorities will facilitate broader implementation of intelligent inhaler technologies while supporting equitable access across diverse healthcare settings.

6. Conclusion

Dry powder inhalers have evolved considerably from conventional pulmonary drug delivery devices into sophisticated therapeutic platforms that increasingly incorporate digital health technologies, artificial intelligence, and connected healthcare infrastructure. This systematic review demonstrates that the integration of smart sensors, wireless communication, cloud computing, AI-assisted analytics, and remote patient monitoring significantly expands the clinical functionality of DPI systems beyond medication delivery alone.

The reviewed evidence indicates that digitally integrated inhalers improve objective adherence monitoring, facilitate early identification of inhalation errors, strengthen clinician–patient communication, and support personalized respiratory disease management. These technological advances are particularly relevant for chronic conditions such as asthma and COPD, where long-term adherence and correct inhalation technique remain major determinants of therapeutic success. The growing maturity of digital inhaler ecosystems described by Aung et al. (2025) further highlights the transition toward continuous, data-driven respiratory care.

The review also demonstrates that technological innovation must be accompanied by equally robust regulatory evolution. Future approval frameworks should address software validation, cybersecurity, interoperability, artificial intelligence governance, and post-market surveillance alongside traditional pharmaceutical quality assessment. Such integrated regulation will be essential for ensuring patient safety while encouraging responsible innovation.

Overall, digitally enabled dry powder inhalers represent a significant advancement in respiratory medicine by combining pharmaceutical engineering with intelligent healthcare technologies. Continued interdisciplinary collaboration among pharmaceutical scientists, biomedical engineers, clinicians, software developers, and regulatory agencies will be critical for realizing the full clinical potential of these systems. Future research should prioritize large-scale clinical validation, standardized performance metrics, ethical governance of patient data, and globally harmonized regulatory frameworks to accelerate the safe implementation of next-generation intelligent inhaler technologies.

References

1. Aung HWW, Murphy A, Greening NJ, The evolving landscape of digital inhaler platforms and adherence support in chronic airways disease. Chronic Respir Dis, 2025;22:1-15.
2. Capstick TGD, Gudimetla S, Harris DS, Malone R, Usmani OS, Demystifying dry powder inhaler resistance with relevance to optimal patient care. Clin Drug Investig, 2024;44:109-114.
3. de Boer AH, Hagedoorn P, Hoppentocht M, Buttini F, Grasmeijer F, Frijlink HW, Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499-512.
4. Fan Z, Ye Y, Chen J, Ma Y, Zhu J, Development of an AI-empowered novel digital monitoring system for inhalation flow profiles. Sensors, 2025;25:4402.
5. Kainu A, Successful use of Easyhaler dry powder inhaler in patients with chronic obstructive pulmonary disease: analysis of peak inspiratory flow from three clinical trials. Pulm Ther. 2024;10:133-142.
6. Kocks JWH, Identifying critical inhalation technique errors in dry powder inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multicountry cross-sectional observational PIFotal study. BMC Pulm Med, 2023;23:302.
7. Palem CR, Comprehensive Review on Dry Powder Inhalations: Mechanisms, Technologies, and Future Directions. American Journal of PharmTech Research, 2025.
8. Palem CR, Lekkala VK, Nagamalli NK, Balguri PR, Gumudevelli S, Next-generation dry powder inhalers: advances in characterization and evolving regulatory frameworks. J Pharm Sci, 2025;1(9):160-177.
9. Palem CR, Nagamalli NK, Paidi VS, Lekkala VK, Rendla R, Gumudevelli S, Dry powder inhalation device development and patent challenges: a comprehensive review. J Pharm Sci, 2025;1(12):436-453.
10. Palem CR, Noolu P, Chilukoti V, Balguri PR, Nagamalli NK, Gumudevelli S. Design and evaluation of controlled-release floating metformin HCl tablets: Influence of binder and granulation process on buoyancy. J Pharm Res Int, 2025;37(12):234-244.
11. Palem CR, Rendla R, Nagamalli NK, Lekkala VK, Gumudevelli S, A comprehensive review of current trends and regulatory frameworks in generic drug development. J Pharm Sci, 2025;1(10):16-27.
12. Pleasants RA, Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease. Respir Med, 2022;205:107038.
13. Watson A, Wilkinson TMA, Digital healthcare in COPD management: a narrative review on the advantages, pitfalls, and need for further research. Ther Adv Respir Dis, 2022;16:1-23.
14. Xiroudaki S, Schoubben A, Giovagnoli S, Rekkas DM, Dry powder inhalers in the digitalization era: current status and future perspectives. Pharmaceutics, 2021;13:1455.